Article
Preclinical Characterization and In Vivo Efficacy of GSK8853, a Small-Molecule Inhibitor of the Hepatitis C Virus NS4B Protein.
Antimicrobial agents and chemotherapy - 1 Oct 2015
Pouliot Jeffrey J, Thomson Michael, Xie Mi, Horton Joseph, Johnson John, Krull David, Mathis Amanda, Morikawa Yoshio, Parks Derek, Peterson Richard, Shimada Takashi, Thomas Elizabeth, Vamathevan Jessica, Van Horn Stephanie, Xiong Zhiping, Hamatake Robert, Peat Andrew J
Abstract excerpt
The hepatitis C virus (HCV) NS4B protein is an antiviral therapeutic target for which small-molecule inhibitors have not been shown to exhibit in vivo efficacy. We describe here the in vitro and in vivo antiviral activity of GSK8853, an imidazo[1,2-a]pyrimidine inhibitor that binds NS4B protein. GSK8853 was active against multiple HCV genotypes and developed in vitro resistance mutations in both genotype 1a and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.